Longitudinal Analysis of Inflammatory Response to SARS-CoV-2 in the Upper Respiratory Tract Reveals an Association with Viral Load, Independent of Symptoms상부 호흡기에서 SARS-CoV-2에 대한 염증 반응의 종단 분석은 증상과 무관한 바이러스 부하와의 연관성을 보여줍니다Observational Study Published on 2021-09-282022-09-12 Journal: Journal of Clinical Immunology [Category] MERS, SARS, 임상, 진단, [키워드] Activation active site analyzed Anosmia antiviral response CCL2 collected conducted Control correlated COVID-19 cohort CXCL10 cytokine cytokine level cytokine levels cytokine response Cytokines different time point different time points dissemination elevated enrolled Geneva University Hospitals GM-CSF IgA IgG IL-6 immunological characteristics increase in Increases increases in independent of innate response intranasal load Local longitudinal Mild myeloid cells nasal Nasal cavity nasal epithelium Nasal wash observational study Patient produced recruitment remained respiratory response Result S1 domain Sample SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2-infected patient SARS-CoV-2-infected patients serum serum cytokine levels specimen Spike protein subset supplementary material Switzerland Symptom symptom onset Symptoms the spike protein therapeutic approaches tract understanding upper upper respiratory tract Viral load Virological virological and immunological characteristics virus [DOI] 10.1007/s10875-021-01134-z PMC 바로가기 [Article Type] Observational Study
Safety and Immunogenicity of a Newcastle Disease Virus Vector-Based SARS-CoV-2 Vaccine Candidate, AVX/COVID-12-HEXAPRO (Patria), in PigsResearch Article Published on 2021-09-212022-10-29 Journal: mBio [Category] COVID-19, SARS, [키워드] acute respiratory syndrome addition Administered Adverse reaction Antigen approved B.1.1.7 B.1.351 candidate Combination coronavirus coronavirus disease coronavirus vaccine COVID-19 dose Effectiveness Efficacy expressing HexaPro Immunity immunogenic immunogenicity include induce intramuscular intranasal intranasally mucosal NDV newcastle disease virus P.1 pig pig model PIGS prefusion conformation proline substitution prolines reactivity responses Safe Safety SARS-CoV-2 SARS-CoV-2 spike protein SARS-CoV-2 vaccine Serum neutralizing antibody spike spike variant tested the vaccine Vaccine [DOI] 10.1128/mBio.01908-21 PMC 바로가기 [Article Type] Research Article
A Combination Adjuvant for the Induction of Potent Antiviral Immune Responses for a Recombinant SARS-CoV-2 Protein Vaccine재조합 SARS-CoV-2 단백질 백신에 대한 강력한 항바이러스 면역 반응 유도를 위한 조합 보조제Immunology Published on 2021-09-162022-09-11 Journal: Frontiers in Immunology [Category] SARS, 변종, 진단, [키워드] activate Adaptive immune response adaptive immune responses adjuvant adjuvants antibody Antibody titers Antigen B.1.351 breadth candidate cellular response Combination cross-protection effective elicited ENhance Heterologous homologous Immune profile immune responses Immunity IMPROVE induction intranasal intranasal vaccine mice mucosal mucosal adjuvant N501Y mutation nanoemulsion (NE) neutralizing antibody titers NLRP3 P.1 variants passive transfer potent recombinant response RIG-I RIG-I agonist RNA robust SARS-CoV-2 SARS-CoV-2 vaccine SARS-CoV-2 variant SARS-CoV-2 variants Spike protein TLR TLRs transfer vaccination variant variants variety Viral viral challenge virus-neutralizing antibody [DOI] 10.3389/fimmu.2021.729189 PMC 바로가기 [Article Type] Immunology
Repurposing of a clinically used anti-HPV agent to prevent and treat SARS-CoV-2 infection as an intranasal formulation비강 내 제형으로 SARS-CoV-2 감염을 예방 및 치료하기 위해 임상적으로 사용되는 항-HPV 제제의 용도 변경Comment Published on 2021-08-262022-09-10 Journal: Signal Transduction and Targeted Therapy [Category] MERS, SARS, 신약개발, 치료제, [키워드] clinically Drug development intranasal Prevent repurposing SARS-COV-2 infection Target validation treat [DOI] 10.1038/s41392-021-00737-7 PMC 바로가기 [Article Type] Comment
Inhalation monoclonal antibody therapy: a new way to treat and manage respiratory infectionsReview Published on 2021-08-232023-06-15 Journal: Applied Microbiology and Biotechnology [Category] MERS, SARS, [키워드] Inhaled delivery intranasal Prophylactic respiratory viral infections SARS-CoV-2 therapeutic antibodies [DOI] 10.1007/s00253-021-11488-4 PMC 바로가기 [Article Type] Review
SARS-CoV-2 disease severity and transmission efficiency is increased for airborne compared to fomite exposure in Syrian hamstersArticle Published on 2021-08-172022-10-04 Journal: Nature Communications [Category] MERS, SARS, 진단, [키워드] Anti-inflammatory cause changes in characterized Contact dependent on disease disease manifestation disease severity driven by Efficiency hamster immune increase in intranasal magnitude Manifestations outcome Pathogenesis pathogenic pathology respiratory virus SARS-CoV-2 SARS-CoV-2 disease SARS-CoV-2 evolution SARS-COV-2 infection SARS-CoV-2 transmission severity subject susceptible Transmission transmission route Viral transmission virus load weight loss [DOI] 10.1038/s41467-021-25156-8 PMC 바로가기 [Article Type] Article
Oral Bacteria Combined with an Intranasal Vaccine Protect from Influenza A Virus and SARS-CoV-2 Infection비강내 백신과 결합된 구강 박테리아는 인플루엔자 A 바이러스 및 SARS-CoV-2 감염으로부터 보호합니다Research Article Published on 2021-08-172022-09-12 Journal: mBio [Category] MERS, SARS, 신종인플루엔자, 진단, [키워드] activating acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 adaptive Adaptive immune response adaptive immune responses adjuvant Administered administration Antibiotics Antibody Response Bacteria Bacterial bacterial pathogen Combined commensal bacteria coronavirus Critical demonstrated Disruption gut microbiota healthy immune responses Immunity induce Infection Influenza Influenza virus intranasal intranasal vaccine intranasally less lysozyme mucosal mucosal immunity mucosal surface MYD88 nasal oral oral cavity PAMPs pathogen-associated molecular pattern PROTECT SARS-CoV-2 severe acute respiratory syndrome Coronavirus signaling pathway significantly lower Vaccine Vaccines virus infection [DOI] 10.1128/mBio.01598-21 PMC 바로가기 [Article Type] Research Article
Single-Dose Intranasal Administration of AdCOVID Elicits Systemic and Mucosal Immunity against SARS-CoV-2 and Fully Protects Mice from Lethal ChallengeArticle Published on 2021-08-092022-10-28 Journal: Vaccines [Category] COVID-19, [키워드] acute respiratory syndrome Adenovirus Adenovirus Vector CD4 CD8 challenge coronavirus coronavirus disease COVID-19 cytokine expression profile dose effective elicit elicited IgA immune response Immunity intramuscular intranasal K18-hACE2 mice lethal Mortality mucosal mucosal immunity nasal mucosa Neutralizing antibodies pandemic Prevent promote Prophylactic RBD Receptor binding domain respiratory tract SARS-CoV-2 SARS-CoV-2 entry serum Spike protein Spread sustained systemic T cell tested the receptor-binding domain the SARS-CoV-2 transgenic mice vaccination Vaccine vaccine candidate Viral vector weight loss [DOI] 10.3390/vaccines9080881 PMC 바로가기 [Article Type] Article
Intranasal type I interferon treatment is beneficial only when administered before clinical signs onset in the SARS-CoV-2 hamster model비강 내 I형 인터페론 치료는 SARS-CoV-2 햄스터 모델에서 임상 징후가 발병하기 전에 투여할 때만 유익합니다.Research Article Published on 2021-08-092022-09-10 Journal: PLoS Pathogens [Category] SARS, 치료제, [키워드] Administered administration Antiviral caused Clinical course Clinical sign clinical trial clinical trials COVID-19 patients days post-infection Deleterious deleterious effects demonstrated disease Effect effector Efficacy and safety Evidence had no Host IFN-α IFNs immunopathology Impaired Infection information interferon interferons Intervention intranasal lung titers MERS MERS-CoV mice modulate observation onset of symptom onset of symptoms patients Post-infection preclinical study produced provide provided SARS-CoV SARS-CoV-2 SARS-COV-2 infection severe COVID-19 shown Signaling Stage the SARS-CoV-2 the timing Therapeutics Treatment Type Type I IFN type I IFNs type I interferon type I interferons Viral viral infections weight loss [DOI] 10.1371/journal.ppat.1009427 PMC 바로가기 [Article Type] Research Article
One or two dose regimen of the SARS-CoV-2 synthetic DNA vaccine INO-4800 protects against respiratory tract disease burden in nonhuman primate challenge modelSARS-CoV-2 합성 DNA 백신 INO-4800의 1회 또는 2회 투여 요법은 비인간 영장류 챌린지 모델에서 호흡기 질환 부담으로부터 보호Article Published on 2021-08-092022-09-12 Journal: Vaccine [Category] MERS, SARS, 비임상, 진단, [키워드] administration binding clinical evaluation controls COVID-19 COVID-19 pandemic disease DNA DNA vaccine dose dose regimen effective vaccine Efficacy evaluated histopathological immunized INO-4800 intranasal lung lung tissue medical countermeasure Neutralizing antibodies Nonhuman Primate Virus Challenge pfu primate PROTECT provided reduced regimen respiratory tract rhesus robust SARS-CoV-2 significantly Spike protein T cell the SARS-CoV-2 vaccination vaccine candidate vaccine-induced immune response virus load [DOI] 10.1016/j.vaccine.2021.06.057 PMC 바로가기 [Article Type] Article